Advertisement

Digestive Diseases and Sciences

, Volume 54, Issue 2, pp 282–291 | Cite as

Clinical Significance of MCM-2 and MCM-5 Expression in Colon Cancer: Association with Clinicopathological Parameters and Tumor Proliferative Capacity

  • Constantinos Giaginis
  • Maria Georgiadou
  • Konstantina Dimakopoulou
  • Gerasimos Tsourouflis
  • Elisavet Gatzidou
  • Gregorios Kouraklis
  • Stamatios TheocharisEmail author
Original Paper

Abstract

Minichromosome maintenance (MCM) proteins are essential components of DNA replication, being related to cell proliferation, and serve as useful markers for cancer screening, surveillance, and prognosis. Our aim was to examine the clinical significance of MCM-2 and MCM-5 protein expression in colon cancer and to evaluate the association with various clinicopathological characteristics and tumor proliferative capacity. Immunohistochemical expression of MCM-2 and MCM-5 was performed on paraffin-embedded malignant tissue sections obtained from 96 patients with colon cancer. MCM-2 and MCM-5 expression was correlated with different clinicopathological characteristics, proliferative capacity (Ki-67 labeling index), and p53 cell-cycle regulator expression. MCM-2 and Ki-67 expression was significantly associated with the tumors’ histological grade (P = 0.003), existence of nodular metastases (N) (= 0.003 and P = 0.030, respectively), malignancy on adenoma (P = 0.029 and P = 0.024, respectively), and vascular invasion (= 0.010 and P = 0.011, respectively). MCM-2 expression was additionally associated with Dukes’ stage (= 0.005). Significant positive relationships were found between the expression of MCM-2 or MCM-5 proteins and that of Ki-67 protein (r = 0.963, P-value < 0.001, and = 0.738, P-value < 0.001, respectively), as well as between MCM-2 and MCM-5 proteins (r = 0.745, P-value < 0.001). Significant positive relationships were also observed between the expression of MCM-2 or MCM-5 proteins and that of p53 protein; however, they were consistently lower than the corresponding with Ki-67 protein. No significant association was observed between MCM-5 protein expression and the clinicopathological characteristics examined. The current data suggest that MCM-2 protein expression is significantly associated with important clinicopathological characteristics for patients’ management, being correlated with the cell proliferation state in colon cancer.

Keywords

MCM-2 MCM-5 Ki-67 p53 Cell proliferation Clinicopathological parameters Colon cancer 

References

  1. 1.
    Tye BK (1999) MCM proteins in DNA replication. Annu Rev Biochem 68:649–686. doi: 10.1146/annurev.biochem.68.1.649 PubMedCrossRefGoogle Scholar
  2. 2.
    Bell SP, Dutta A (2002) DNA replication in eukaryotic cells. Annu Rev Biochem 71:333–374. doi: 10.1146/annurev.biochem.71.110601.135425 PubMedCrossRefGoogle Scholar
  3. 3.
    Maiorano D, Lutzmann M, Merchali M (2006) MCM proteins and DNA replication. Curr Opin Cell Biol 18:130–136. doi: 10.1016/j.ceb.2006.02.006 PubMedCrossRefGoogle Scholar
  4. 4.
    Takisawa H, Mimura S, Kubota Y (2000) Eukaryotic DNA replication: from-replication complex to initiation complex. Curr Opin Cell Biol 12:690–696. doi: 10.1016/S0955-0674(00)00153-8 PubMedCrossRefGoogle Scholar
  5. 5.
    Laskey RA, Madine MA (2003) A rotary pumping model for helicase function of MCM proteins at a distance from replication forks. EMBO Rep 4:26–30. doi: 10.1038/sj.embor.embor706 PubMedCrossRefGoogle Scholar
  6. 6.
    Tachibana KK, Gonzalez MA, Coleman N (2005) Cell-cycle-dependent regulation of DNA replication and its relevance to cancer pathology. J Pathol 205:123–129. doi: 10.1002/path.1708 PubMedCrossRefGoogle Scholar
  7. 7.
    Romanowski P, Madine MA (1997) Mechanisms restricting DNA replication to once per cell cycle: the role of Cdc6, ORC. Trends Cell Biol 7:9–10. doi: 10.1016/S0962-8924(97)30077-4 PubMedCrossRefGoogle Scholar
  8. 8.
    Rodins K, Cheale M, Coleman N, Fox SB (2002) Minichromosome maintenance protein 2 expression in normal kidney and renal cell carcinomas: Relationship to tumor dormancy and potential clinical utility. Clin Cancer Res 8:1075–1081PubMedGoogle Scholar
  9. 9.
    Gonzalez MA, Pinder SE, Callagy G, Vowler SL, Morris LS, Bird K, Bell JA, Laskey RA, Coleman N (2003) Minichromosome maintenance protein 2 is a strong independent prognostic marker in breast cancer. J Clin Oncol 21:4306–4313. doi: 10.1200/JCO.2003.04.121 PubMedCrossRefGoogle Scholar
  10. 10.
    Kato H, Miyazaki T, Fukai Y, Nakajima M, Sohda M, Takita J, Masuda N, Fukuchi M, Manda R, Ojima H, Tsukada K, Asao T, Kuwano H (2003) A new proliferation marker, minichromosome maintenance 2, is associated with tumor aggressiveness in esophageal squamous cell carcinoma. J Surg Oncol 84:24–30. doi: 10.1002/jso.10287 PubMedCrossRefGoogle Scholar
  11. 11.
    Scott IS, Morris LS, Bird K, Davies RJ, Vowler SL, Rushbrook SM, Marshall AE, Laskey RA, Miller R, Arends MJ, Coleman N (2003) A novel immunohistochemical method to estimate cell-cycle phase distribution in archival tissue: implications for the prediction of outcome in colorectal cancer. J Pathol 201: 187–197. doi: 10.1002/path.1444 PubMedCrossRefGoogle Scholar
  12. 12.
    Wharton SB, Chan KK, Anderson JR, Stoeber K, Williams CH (2001) Replicative Mcm2 protein as a novel proliferation marker in oligodendrogliomas and its relationship to Ki-67 labeling index, histological grade and prognosis. Nephropathol Appl Neurobiol 27:305–313. doi: 10.1046/j.0305-1846.2001.00333.x CrossRefGoogle Scholar
  13. 13.
    Stoeber K, Tlsty TD, Happerfield L, Thomas GA, Romanov S, Bohrow L, Williamas ED, Willimas GH (2001) DNA replication licensing and human cell proliferation. J Cell Sci 114:2027–2041PubMedGoogle Scholar
  14. 14.
    Davies RJ, Freeman A, Morris LS, Bingham S, Dilworth S, Scott I, Laskey RA, Miller R, Coleman N (2002) Analysis of minichromosome maintenance proteins as a novel method for detection of colorectal cancer in stool. Lancet 359:1917–1919. doi: 10.1016/S0140-6736(02)08739-1 PubMedCrossRefGoogle Scholar
  15. 15.
    Ishimi Y, Okayasu I, Kato C, Kwon HJ, Kimura H, Yamada K, Song SY (2003) Enhanced expression of MCM proteins in cells derived from the uterine cervix. Eur J Biochem 270:1089–1101. doi: 10.1046/j.1432-1033.2003.03440.x PubMedCrossRefGoogle Scholar
  16. 16.
    Williams GH, Swinn R, Prevost AT, De Clive-Lowe P, Halsall I, Going JJ, Hales CN, Stoeber K, Middleton SJ (2004) Diagnosis of oesophageal cancer by detection of minichromosome maintenance 5 protein in gastric aspirates. Br J Cancer 91:714–719PubMedGoogle Scholar
  17. 17.
    Scott IS, Morris LS, Rushbrook SM, Bird K, Vowlert SL, Burnet NG, Coleman N (2005) Immunohistochemical estimation of cell cycle entry and phase distribution in astrocytomas: applications in diagnostic neuropathy. Neuropath Appl Neurobiol 31:455–466. doi: 10.1111/j.1365-2990.2005.00618.x CrossRefGoogle Scholar
  18. 18.
    Ramnath N, Hernandez FJ, Tan D-F, Huberman JA, Natarajan N, Beck AF, Hyland A, Todorov IT, Brooks JS, Bepler G (2001) MCM2 is an independent predictor of survival in patients with non-small-cell lung cancer. J Clin Oncol 19:4259–4266PubMedGoogle Scholar
  19. 19.
    Guida T, Salvatore G, Faviana P, Giannini R, Garcia-Rostan G, Provitera L, Basolo F, Fusco A, Carlomagno F, Santoro M (2005) Mitogenic effects of the up-regulation of the minichromosome maintenance proteins in anaplastic thyroid carcinoma. J Clin Endocrinol Metab 90:4703–4709. doi: 10.1210/jc.2004-2459 PubMedCrossRefGoogle Scholar
  20. 20.
    Meng MV, Grossfeld GD, Williams GH, Dilworth S, Stoeber K, Mulley TW, Weinberg V, Carroll PR, Tlsty TD (2001) Minichromosome maintenance protein 2 expression in prostate: Characterization and association with outcome after therapy for cancer. Clin Cancer Res 7:2712–2718PubMedGoogle Scholar
  21. 21.
    Stoeber K, Halsall I, Freeman A, Swinn R, Doble A, Morris L, Coleman N, Bullock N, Laskey RA, Hakes CN, Williams GH (1999) Immunoassay for urothelial cancers that detects DNA replication protein Mcm5 in urine. Lancet 354:1524–1525. doi: 10.1016/S0140-6736(99)04265-8 PubMedCrossRefGoogle Scholar
  22. 22.
    Korkolopoulou P, Givalos N, Saetta A, Goudopoulou A, Gakiopoulou H, Thymara I, Thomas-Tsagli E, Patsouris E (2005) Minichromosome maintenance proteins 2 and 5 expression in muscle-invasive urothelial cancer: a multivariate survival study including proliferation markers and cell cycle regulators. Human Pathology 36:899–907. doi: 10.1016/j.humpath.2005.06.008 PubMedCrossRefGoogle Scholar
  23. 23.
    Burger M, Denzinger S, Hartmann A, Wieland W-F, Stoehr R, Obermann EC (2007) Mcm2 predicts recurrence hazard in stage Ta/T1 bladder cancer more accurately than CK20, Ki67 and histological grade. Br J Cancer 96:1711–1715. doi: 10.1038/sj.bjc.6603784 PubMedCrossRefGoogle Scholar
  24. 24.
    Midgley R, Kerr D (1999) Colorectal cancer. Lancet 353:391–399. doi: 10.1016/S0140-6736(98)07127-X PubMedCrossRefGoogle Scholar
  25. 25.
    Green FL, Page DL, Fleming ID, Fritz A, Balch CM, Haller DG, Morrow M (eds) (2002) Cancer staging manual, 6th edn. Springer Verlag, New York, NYGoogle Scholar
  26. 26.
    Sobin LH, Wittekind C (eds) (2002) TNM classification of malignant tumors, 6th edn. Wiley, New York, NYGoogle Scholar
  27. 27.
    Altman DG, Bland JM (1994) Quartiles, quintiles, centiles and other quantiles. BMJ 309: 996PubMedGoogle Scholar
  28. 28.
    Kushner J, Bradley G, Jordan R CK (1997) Patterns of p53 and ki-67 protein expression in epithelial dysplasia from the floor of the mouth. J Pathol 183: 418–423. doi: 10.1002/(SICI)1096-9896(199712)183:4<418::AID-PATH946>3.0.CO;2-T PubMedCrossRefGoogle Scholar
  29. 29.
    Stoeber K, Swinn R, Prevost AT, Clive-Lowe P, Halsall I, Dilworth SM, Marr J, Turner WH, Bullock N, Doble A, Hales CN, Williams GH (2002) Diagnosis of genitor-urinary tract cancer by detection of minichromosome maintenance 5 protein in urine sediments. J Natl Cancer Inst 94:1071–1079PubMedGoogle Scholar
  30. 30.
    Murphy N, Ring M, Heffron CC, King B, Killalea AG, Hughes C, Martin CM, McGuinness E, Sheils O, O’Leary JJ (2005) p16INK4A, CDC6 and MCM5: predictive biomarkers in cervical preinvasive neoplasia and cervical cancer. J Clin Pathol 58:525–534. doi: 10.1136/jcp.2004.018895 PubMedCrossRefGoogle Scholar
  31. 31.
    Freeman A, Morris LS, Mills AD, Stoeber K, Lasket RA, Williams GH, Coleman N (1999) Minichromosome maintenance proteins as biological markers of dysplasia and malignancy. Clin. Cancer Res 5:2121–2132PubMedGoogle Scholar
  32. 32.
    Going JJ, Keith WN, Neilson L, Stoeber K, Stuart RC, Williams GH (2002) Aberrant expression of minichromosome maintenance proteins 2 and 5, and Ki-67 in dysplastic squamous oesophageal epithelium and Barrett’s mucosa. Gut 50:373–377. doi: 10.1136/gut.50.3.373 PubMedCrossRefGoogle Scholar
  33. 33.
    Kodani I, Shomori K, Osaki M, Kuratate I, Ryoke K, Ito H (2001) Expression of minichromosome maintenance 2 (MCM2), Ki-67 and cell-cycle-related molecules, and apoptosis in the normal-dydplasia-carcinoma sequence of the oral mucosa. Pathobiology 69:150–158. doi: 10.1159/000048770 PubMedCrossRefGoogle Scholar
  34. 34.
    Brown DC, Gatter KC (2002) Ki67 protein: the immaculate deception? Histopathology 40:2–11. doi: 10.1046/j.1365-2559.2002.01343.x PubMedCrossRefGoogle Scholar
  35. 35.
    Mehrotra P, Gonzalez MA, Johnson SJ, Coleman N, Wilson JA, Davies BR, Lennard TWJ (2006) Mcm-2 and Ki-67 have limited potential in preoperative diagnosis of thyroid malignancy. Laryngoscope 116:1434–1438. doi: 10.1097/01.mlg.0000225931.59644.93 PubMedCrossRefGoogle Scholar
  36. 36.
    Bainsh H, Gerdes J (1987) Simultaneous staining of exponentially growing versus plateau phase cells with the proliferation-associated antibody Ki67 and propidium iodide: analysis by flow cytometry. Cell Tissue Kinet 20:387–391Google Scholar
  37. 37.
    MacCallum DE, Hall PA (2000) The location of pKi67 in the outer dense fibrillary compartment of the nucleolus points to a role in ribosome biogenesis during the cell division cycle. J Pathol 190:537–544. doi: 10.1002/(SICI)1096-9896(200004)190:5<537::AID-PATH577>3.0.CO;2-W PubMedCrossRefGoogle Scholar
  38. 38.
    Toshi L, Bravo R (1988) Changes in cyclin/proliferating cell nuclear antigen distribution during DNA repair synthesis. J Cell Biol 107:1623–1628. doi: 10.1083/jcb.107.5.1623 CrossRefGoogle Scholar
  39. 39.
    Cascinu S, Ligi M, Graziano F, Del Ferro E, Valentini M, Grianti C, Bartolucci M, Catalano G (1998) S-phase fraction can predict event free survival in patients with pT2-T3N0M0 colorectal carcinoma: implications for adjuvant chemotherapy. Cancer 83:1081–1085. doi: 10.1002/(SICI)1097-0142(19980915)83:6<1081::AID-CNCR5>3.0.CO;2-B PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Constantinos Giaginis
    • 1
    • 2
  • Maria Georgiadou
    • 1
  • Konstantina Dimakopoulou
    • 1
  • Gerasimos Tsourouflis
    • 2
  • Elisavet Gatzidou
    • 1
    • 2
  • Gregorios Kouraklis
    • 2
  • Stamatios Theocharis
    • 1
    Email author
  1. 1.Department of Forensic Medicine and Toxicology, Medical SchoolUniversity of AthensAthensGreece
  2. 2.Second Department of Propedeutic Surgery, Laikon Hospital, Medical SchoolUniversity of AthensAthensGreece

Personalised recommendations